Telomir Pharmaceuticals Secures $1 Million in Private Placement
PUBLIC · TELOOct 05, 2026
Amount Raised
$1 Million
Round Type
Post-IPO Equity
BaltimoreBiotechnologyPharmaceuticalBiopharma
Investors
John Paul DeJoria
Description
On October 5, 2026, Telomir Pharmaceuticals, Inc. entered into a securities purchase agreement with various investors to conduct a private placement. The company agreed to issue and sell 4,843,300 shares of common stock as part of this financing round. Notably, John Paul DeJoria, a significant shareholder, participated with a $1 million investment
Company Information
Company
Telomir Pharmaceuticals
Location
900 WEST PLATT STREET, SUITE 200
Baltimore, Maryland, United States
About
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1, the first novel small molecule to lengthen the DNA’s protective telomere caps in order to affect age reversal.
Fundz sees it the moment Telomir Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BaltimoreBiotechnologyPharmaceuticalBiopharma